Navigation Links
Medizone Expects OTCBB Listing
Date:8/5/2009

SAN FRANCISCO, Aug. 5 /PRNewswire-FirstCall/ -- Medizone International, Inc. (Pink Sheets: MZEI) announced that a market maker has filed the required documentation to list the company on the Over The Counter Bulletin Board (OTCBB). The company is currently listed as a full SEC reporting company on the Pink Sheets and expects to achieve a listing on the OTCBB before the end of August 2009.

Medizone will hold its annual meeting of shareholders on August 26, 2009 in Reno, Nevada. At the meeting, officials of the company will update shareholders on the company's business and shareholders will vote on matters presented by the proxy statement on file with the Securities and Exchange Commission and made available electronically to the company's shareholders. In addition to voting on the election of directors, for the first time since the company became a public company in 1986 the shareholders will vote to increase the number of shares the company is authorized to issue. As noted in the proxy statement, the company has historically relied on the sale of its common stock to finance its operations and research and development. A modest portion of the newly authorized shares would facilitate the financing of hospital beta testing and initial production of the company's AsepticSure hospital sterilization system. "Importantly," noted Edwin Marshall, CEO of the company, "the availability of increased authorized capital will also give management greater flexibility for strategic development and other transactions."

Marshall further clarified the business strategy, "Medizone is preparing a transition into the hospital beta testing stage. We now expect to begin hospital testing during October using production prototype equipment. We are targeting initial sales before the end of this year with deliveries during the first quarter of 2010 expected to bring the company to a break-even cash flow. Our initial production rates will be kept on the conservative side until the design proves very reliable in the field and a dramatic increase in production would not offer significant risk. At that point in time we will have optimized our strengths as a research and development company and expect to partner with a multinational corporation in the hospital sector for increased manufacturing capacity, sales and service. The target is to achieve profitability moving into mid-year 2010."

Medizone International, Inc., is a research and development company engaged in developing its AsepticSure(TM) technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. Current trials will now be expanded to include a hospital mock-up and then hospital beta testing of the production prototype. Initial sales are currently targeted to commence by the end of this year.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

    Investor Relations: 800-953-3350 / web site: www.medizoneint.com
    E-mail: operations @ medizoneint.com


'/>"/>
SOURCE Medizone International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medizone International, Inc. Announces Strategic Consulting Relationship With TDV Global, Inc.
2. The Canadian Foundation for Global Health Announces a Research and Development Partnership with Medizone International, Inc.
3. Medizone Announces a Second Round of Trials Have Begun.
4. Medizone Announces That Its AsepticSure(TM) Development Program is Reaching Objectives on Two Fronts
5. Medizone International, Inc. (MZEI.PK) Announces it has Established its Own BSL2A Certified Laboratory Located in Innovation Park, Queens University at Kingston, Ontario, Canada.
6. Medizone International, Inc. Has Filed for Patent Protection for Its AsepticSure(TM) Hospital Sterilization System
7. ReBuilder Medical Technologies, Inc. Contracts with ETS to Manufacture the Newest Version of its ReBuilder Neuropathy Treatment Device; Expects Sales to Increase 30%
8. ATS Medical Expects Fourth Quarter Revenue to Increase by Approximately 32%
9. NightHawk Radiology Holdings, Inc. Announces Preliminary Results of Its Tender Offer; NightHawk Expects to Purchase 2,367,438 Shares of Its Common Stock at $8.05 per Share
10. Chubb Expects to Release Earnings on July 24 and Hold Conference Call on the Same Day
11. ATS Medical Expects Second Quarter Revenue of $16.7 to $16.9 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... ... The Patient Advocacy Community of The Beryl Institute presented Eve DeVaro, Director, Patient ... Award in recognition of her extraordinary contributions to the field of patient advocacy ... Institute’s annual Patient Experience Conference on March 20 in Denver, Colorado. ...
(Date:4/21/2017)... Hong Kong (PRWEB) , ... April 21, 2017 , ... ... Printing (U3DP), the first 3D printing facility among higher education institutions in Hong Kong ... 3D printing, in terms of the range and quantity of facilities in Hong Kong. ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... AWARE: A Week of Addiction and Recovery Education, from April 24 to April ... preventing substance use disorders. , The mission of AWARE is to instill ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... announced an exciting new partnership with the highly regarded and well renowned Asian ... highly innovative, myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize and ...
(Date:4/21/2017)... Worcestershire, UK (PRWEB) , ... April 21, 2017 ... ... Award for Enterprise in the category of International Trade, the UK’s most prestigious ... in international trade, which represents 95% of total revenues and has grown by ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
Breaking Medicine Technology: